CelluNOVA DermoRebirth™
A proprietary rejuvenation blend for brands that want to launch a premium, evidence‑informed line. The full formula is shared only under NDA — no quantities — and final disclosure occurs after contract execution.
Proprietary blend (under NDA)
Flexible licensing models
Technical & regulatory support
Premium positioning
Pilot product
Visual reference (design/packaging). Specifications and suppliers are presented only under NDA.
Market comparison (data‑driven)
High‑level view of leading players and models. DermoRebirth™ keeps composition confidential and is disclosed only under NDA.
| Brand / Product | Core proposal | Positioning angle | Model | Revenue scale | Formula disclosure | Licensing | Notes |
|---|---|---|---|---|---|---|---|
| CelluNOVA DermoRebirth™ | Proprietary composition (under NDA) | Rejuvenation / healthy aging* | B2B licensing; optional exclusivity | — | Confidential | Yes (licensing) | Technical dossier under NDA |
| Elysium Health — Basis | Public composition (NAD+ focus) | Cellular aging / premium subscription* | B2C | Private (not disclosed) | Public (NR + pterostilbene) | No | Official site |
| ChromaDex — Tru Niagen / Niagen® | Public composition (NAD+ focus) | Metabolic health / global portfolio* | B2C + B2B ingredient | ~$100M FY2024 (public) | Public (NR / Niagen®) | Ingredient supply | Public revenue |
Global anti‑aging supplements market ~$4.88B (2025). CAGR near 8% in major sector projections.
*No medical claims. Illustrative values.
Refined benefit comparison — CelluNOVA vs top anti‑aging blends
Illustrative scoring (0–10) across key dimensions. Created for partner presentations; full method under NDA.
Why partners choose DermoRebirth™
- ●Time‑to‑market as fast as 6–12 weeks (depending on partner ops).
- ●5‑pillar bioactive architecture (hydration, cellular energy, oxidation balance, senescence modulation, autophagy support) — details under NDA.
- ●Benchmark gross margin range for premium nutraceuticals: 60–75% (illustrative).
- ●Optional regional/category exclusivity tied to volume commitments.
Licensing models
Optional exclusivity by region/line, scientific dossier under NDA, labeling/regulatory support and launch materials.
Or email us directly at: larissa.guimaraes@cellunovaresearch.com